| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Levothyroxine Sodium (L-T4 sodium, LT4 sodium, LT4 sodium, L-Thyroxine sodium), a major thyroid hormones involved in the maintenance of metabolic homeostasis, is an endogenous agonist of Thyroid hormone receptor alpha and beta.
| ln Vivo |
Deiodinase (DIO), which catalyzes the conversion of adrenaline (cortogen) into active adrenal cortex, corresponds with catalytic adrenaline (TSH) levels. DIO1 and DIO2 accelerate the activation of the adrenal cortex, while DIO3 is reduced to inactivity. The actions of DIO1 and DIO2 play a critical role in the negative feedback control of pituitary TSH [1]. L-Thyroxine sodium (T4) and triprostaglandin (T3) fisheries are known to affect ion channels, pumps and modulatory characteristics. Additionally, pancreatic islet hormones have been demonstrated to impact the expression of arcticin and proteins involved for excitability and contractility, L- Insulin and triiodothyronine govern its pharmacological regulation and. In the 12-week cohort, significantly lower levels of triiodothyronine and L-thyroxine were reported compared with controls fed a conventional diet. In the group treated with low-dose L-thyroxine, an increase in L-thyroxine levels was seen, although triiodothyronine levels remained practically similar to those in the thyroid gland. Circulating concentrations of triiodothyronine and L-pakatin were significantly raised in individuals treated with high-dose L-thyroxine compared with the untreated hypothyroid group, and L-pakatin levels were significantly elevated compared with control values [2 ].
|
|---|---|
| References |
[1]. Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323.
[2]. Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149. |
| Molecular Formula |
C87H63N6OP
|
|---|---|
| Molecular Weight |
1239.4445
|
| CAS # |
55-03-8
|
| Related CAS # |
L-Thyroxine;51-48-9;L-Thyroxine sodium salt pentahydrate;6106-07-6
|
| SMILES |
P12(C3C4=C([H])C5=C([H])C=3N(C3=C([H])C([H])=C(C([H])([H])[H])C6=C([H])C7=C(C([H])([H])[H])C([H])=C([H])C(=C7C([H])=C36)N5C3C([H])=C([H])C(C([H])([H])[H])=C([H])C=3[H])C3=C([H])C5=C([H])C(=C13)N(C1=C([H])C([H])=C(C([H])([H])[H])C3=C([H])C6=C(C([H])([H])[H])C([H])=C([H])C(=C6C([H])=C13)N5C1C([H])=C([H])C(C([H])([H])[H])=C([H])C=1[H])C1=C([H])C3=C([H])C(=C21)N4C1=C([H])C([H])=C(C([H])([H])[H])C2=C([H])C4=C(C([H])([H])[H])C([H])=C([H])C(=C4C([H])=C12)N3C1C([H])=C([H])C(C([H])([H])[H])=C([H])C=1[H])=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~78.24 mM)
0.5 M NaOH : 25 mg/mL (~31.29 mM) H2O : ~14 mg/mL (~17.53 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (2.60 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8068 mL | 4.0341 mL | 8.0682 mL | |
| 5 mM | 0.1614 mL | 0.8068 mL | 1.6136 mL | |
| 10 mM | 0.0807 mL | 0.4034 mL | 0.8068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
